Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

Abstract Background Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2-mediated glucose reabsorption in renal proximal tubules, have shown pr...

Full description

Bibliographic Details
Main Authors: Annayya R. Aroor, Nitin A. Das, Andrea J. Carpenter, Javad Habibi, Guanghong Jia, Francisco I. Ramirez-Perez, Luis Martinez-Lemus, Camila M. Manrique-Acevedo, Melvin R. Hayden, Cornel Duta, Ravi Nistala, Eric Mayoux, Jaume Padilla, Bysani Chandrasekar, Vincent G. DeMarco
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Cardiovascular Diabetology
Subjects:
Vascular stiffness
Renal resistivity
SGLT2
RECK
Pulsatility index
Online Access:http://link.springer.com/article/10.1186/s12933-018-0750-8

Internet

http://link.springer.com/article/10.1186/s12933-018-0750-8

Similar Items